anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nausea and vomiting, which may be severe, can happen with APOKYN when it is administered at recommended doses. Because of this, in domestic clinical studies, 98% of all patients were premedicated with trimethobenzamide, an antiemetic, for three days prior to study enrollment, and were then encouraged to continue trimethobenzamide for at least 6 weeks. Even with the use of concomitant trimethobenzamide in clinical studies, 31% and 11% of the APOKYN-treated patients had nausea and vomiting, respectively, and 3% and 2% of the patients discontinued APOKYN due to nausea and vomiting, respectively. Among 522 patients treated, 262 (50%) discontinued trimethobenzamide while continuing APOKYN. The average time to discontinuation of trimethobenzamide was about 2 months (range: 1 day to 33 months). For the 262 patients who discontinued trimethobenzamide, 249 patients continued apomorphine without trimethobenzamide for a duration of follow-up that averaged 1 year (range: 0 years to 3 years).

The effect of trimethobenzamide on reducing nausea and vomiting during treatment with APOKYN was evaluated in a 12-week, placebo-controlled study in 194 patients. The study suggests that trimethobenzamide reduces the incidence of nausea and vomiting during the first 4 weeks of APOKYN treatment (incidence of nausea and vomiting 43% on trimethobenzamide vs. 59% on placebo). However, over the 12-week period, compared with placebo, patients treated with trimethobenzamide had a greater incidence of somnolence (19% for trimethobenzamide vs. 12% for placebo), dizziness (14% for trimethobenzamide vs. 8% for placebo), and falls (8% for trimethobenzamide vs. 1% for placebo). Therefore, the benefit of treatment with trimethobenzamide must be balanced with the risk for those adverse events, and treatment with trimethobenzamide should only be continued as long as necessary to control nausea and vomiting, and generally no longer than two months.

The ability of concomitantly administered antiemetic drugs (other than trimethobenzamide) has not been studied. Antiemetics with anti-dopaminergic actions (e.g., haloperidol, chlorpromazine, promethazine, prochlorperazine, metaclopramide) have the potential to worsen the symptoms in patients with Parkinson's disease and should be avoided.
In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
<P>PROBLEM TO BE SOLVED: To provide a phosphoric acid adsorbent composed of a resin capable of adsorption of phosphoric acid, and a method for phosphoric acid adsorption.  <P>SOLUTION: The phosphoric acid adsorbent is composed of a resin shown by general formula [I]. The resin is composed of an anion exchange resin and a chelate resin shown by formulae [VI] and [VII]. The anion exchange resin is capable of adsorption of oxalic acid in addition to phosphoric acid. While the chelate resin also can adsorb lanthanum and aluminum ions.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
LPV/RTV has shown significant antiviral activity and tolerability in clinical trials in adults and children over 6 months of age. LPV/RTV has been approved by the FDA to treat older children and adults with HIV. Data for children under 6 months, however, have not been available. LPV/RTV has not been approved for infants less than 6 months old, and the appropriate dose for young infants is not known. Dosing guidelines are needed for young infants, most of whom are in the early stages of primary infection. This study will help identify an appropriate dose range of LPV/RTV and evaluate response to therapy in infants less than 6 months of age. The study will also evaluate whether early therapy allows normal development of the immune system.

Infants between 14 days and 6 months of age will receive LPV/RTV in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their physicians. Twelve-hour pharmacokinetic sampling is performed on Day 14 of drug treatment and when the patient reaches 12 months of age. Patients will undergo a physical exam, medical history assessment, and blood collection at selected study visits. Study visits will occur every 2 weeks for the first 8 weeks, then every 4 weeks until the end of the first year of the study. Study visits during the second year will be every 12 weeks until the end of the study. The parent or guardian will be contacted by phone every 6 weeks to monitor adverse drug effects. Participants between the ages of 6 weeks but less than 6 months old will be followed for 96 weeks after the enrollment of the last participant. Participants between the ages of 14 weeks but less than 6 weeks will be followed for 48 weeks after the enrollment of the last participant.
The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.
PCT No. PCT/EP95/04201 Sec. 371 Date Mar. 25, 1996 Sec. 102(e) Date Mar. 25, 1996 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/13517 PCT Pub. Date May 9, 1996The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and said peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compositions comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method.
Invention refers to heterocyclic compounds, in particular to reception of derivatives of 1,2,5,6- TETRAHYDROPYRIDINE-3-CARBOXAL of the formula 1 NOR=CH-C=CH-CH-  CH-N  (R)  - CH where R-H or methyl, R-linear and whether branched out saturated C-alkyl , linear or branched out nonsaturated C-alkyl , acetyl or dimethylaminoethy, or their hydrochlorides possessing cholinomimetic activity.         Technical result of the invention - revealing of new more active compounds of the specified class. Reception of target products is conducted from a hydrochloride of the formula CHO-C=CH-CH-CH-N   (R-CH)   where R is specified above, and a hydrochloride of the formula NHORа  , where Rа -H, linear or branched out saturated C-alkyl , linear or branched out nonsaturated C-alkyl . The gained compound of the formula IA NORа  =CH-CH-CH-CH-N   (R)  - CH where R and Rа- are specified above, is isolated in a free aspect or in the form of a hydrochloride, and in case of when Rа -H, the compound of the formula IA is subjected to interacting with compund Ra -HаI where RB  - acetyl or dimethylethylaminoethyl, HаI-halogen. The gained compound of the formula NORB  =CH-C=CH-CH- CH-N  (R)  - CH where R and RB  - are specified above, is isolated in a free aspect or in the form of a hydrochloride.            3 tab.
A 65-year-old man presented with a 15-year history of belching, accompanied by intermittent epigastric pain. She had undergone abdominal computed tomography 5 years earlier, which showed a cystic mass in the gastric cardia (asterisk), measuring 4 cm × 3 cm in size. His symptoms worsened recently, especially when consuming stimulating food or after emotional excitement. Repeated abdominal computed tomography showed similar cystic mass in the gastric cardia (asterisk), with small quantity of peripheral calcification. Laparoscopic resection of the cystic mass was performed. Histopathologic examination confirmed the diagnosis of bronchogenic cyst, with internal coffee colored liquid and partial cyst wall calcification. The symptom of belching disappeared after surgery and the patient was feeling well at 2 months of follow-up.
E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
C:\NRPonb\DCC\WAMM$9Y3112_1 OC-69/2012 The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, prematized or humanized antibodies or fragments, having altered ability to meditate cell signaling activity by a target antigen, and/or altered ability to meditate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modified ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. WO 2007/03 1875 PCTIIB2006/003294 - 24/ 28 C'C4 min IM I ~jUeewu oe6
PURPOSE: To obtain a promoting agent containing a Cirsium plant as an active ingredient, having a clear fat degradation-promoting action in fat tissues, and exhibiting excellent effects on the inhibition, prevention and improvement of obesity. CONSTITUTION: This fat degradation-promoting agent contains a Cirsium plant (preferably Cephalonoplos segetum (Bieb.) Kitam., Cephalonoplos setosum (Biel.) Kitam., Cirsium borealinipponense Kitam., etc.) as an active ingredient. The roots and stems of the Cirsium plant are preferably used, and may be used in the form of the raw state, dry powder solvent extract, etc. The Cirsium plant is preferably compounded in an amount of 0.001-30wt.% converted into the dry product of the solvent extract in the composition on an external preparation and in an amount of 1-2g (converted into the dry product of the solvent extract) per day for an adult on an oral administration preparation. When contained in the external preparation for skin, the objective promoting agent may further be compounded with a xanthine derivative, β-adrenaline action- stimulating medicine, etc.
Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
Apart from the legs, restless legs syndrome (RLS) also affects the arms, head, neck, face, oral cavity, genital area, abdomen, intestines and bladder. RLS is also linked to several comorbid diseases, including headache disorders. Its association with dizziness has never been explored. We are reporting on two patients with RLS who also had a history of chronic dizziness. The treatment with levodopa or dopamine agonists completely alleviated both RLS and dizziness. We propose that RLS-like symptoms in the head may be experienced as dizziness and that dizziness may be part of the symptom complex of RLS. A large number of patients with chronic dizziness remain undiagnosed in clinical practice. We suggest exploring the history of RLS in patients presenting with chronic dizziness. Such patients may respond to levodopa or dopamine agonists. Because the response was seen in only two patients, a prospective placebo-controlled trial is needed to confirm these findings.
The utility model discloses an evaporator with a parallel plate type heat exchanger, composed of an evaporation chamber and a parallel plate type heat exchanger. The left lower part of the evaporation chamber is provided with liquid-lifting circulation pipe whose end is connected with a three-way pipe. Each port of the three-way pipe is respectively connected with a three-way draining valve that is connected with the discharging pipe of the plate type heat exchanger. The right lower side of a salt receiver is connected with a down flow circulation pipe which is connected with a circulation pump which is connected with the three-way pipe. Each port of the three-way pipe is matched with a three-way inlet valve, and a valve port is connected with the feed pipe of the plate type heat exchanger. The lower part of the plate type heat exchanger is provided with a steam inlet tube and a condensed water discharge pipe. Any plate type heat exchanger can be overhauled and washed in the condition of normal operation.
Patients treated for Parkinson’s disease have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event. In controlled clinical trials, somnolence and fatigue were reported as adverse reactions in 4% of patients treated with GOCOVRI 274 mg and 1% for placebo.

Before initiating treatment with GOCOVRI, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with GOCOVRI, such as concomitant sedating medications or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued.

If a decision is made to continue GOCOVRI, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living or daytime somnolence.
Three patients will be orally dosed at 100 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 3 (\<1/6 DLT), de-escalate to lower dose or stop (\>1/6 DLT).
Despite clear evidence of improved health outcomes with regular exercise (see Bliss et al., 2021; Kleinloog et al., 20,22 for recent reviews), national statistics suggest that a mere 48% of Americans meet the recommended levels of physical activity (Centers for Disease Control and Prevention \[CDC\], 2018). Alarmingly, fewer than 30% of African American women living in public housing meet these recommended levels, marking the lowest rate among all demographic groups (Lee \& Im, 2010; Hilland et al., 2020). Cerebrovascular disease in this population is increasing in prevalence, as is early presentation underscoring the urgent need for innovative, culturally relevant strategies to promote and study the effects of physical activity engagement within this under-resourced community (Turney et al., 2022; Zuellsdorf et al., 2020). However, developing relevant research-based interventions requires understanding and adapting specific programs to local public housing challenges (Casagrande et al., 2008). Mistrust is the primary barrier to relationship development in this population, and engagement with an established community partner is critical for local implementation. This proposal aims to develop a physical activity education program for women at high risk of disease to promote healthy lifestyles and mitigate the risk of neurological pathology.
FIELD: biology, biochemistry, medicine. SUBSTANCE: invention relates to dry partially amorphous products that comprise an active component and stabilizing mixtures of substances including at least two components. One substance of a stabilizing mixture is taken among a group comprising monosaccharides, disaccharides and zwitterion with a polar residue. The indicated zwitterion means arginine, aspartic acid, citrulline, glutamic acid, ornithine, histidine, lysine. The second substance of a stabilizing mixture is a zwitterion with a nonpolar residue and means acetylphenylalanine ester, alanine, cysteine, glycine, leucine, methionine, tryptophan, valine, sarcosine. Biologically active material means peptides, proteins, glycoproteins, antibodies, viruses, vaccines, cells and other substances. According to a method of preparing amorphous products the solution of biologically active component and indicated stabilizing substances are prepared and then solution is dried without its freezing. Stabilized biological materials show stability in storage at the room temperature and can be used for diagnosis and therapeutic aims. EFFECT: improved method of preparing. 20 cl, 3 dwg, 29 tbl
BACKGROUND: Residual disease following cytoreductive surgery in patients with ovarian cancer has been associated with poorer survival outcomes compared with no residual disease. We performed a meta-analysis to assess the impact of varying levels of residual disease status on survival outcomes in patients with ovarian cancer who have undergone primary cytoreductive surgery or interval cytoreductive surgery in the setting of new therapies for this disease.
METHODS: Medline, Embase, and Cochrane databases (January 2011 - July 2020) and grey literature, bibliographic and key conference proceedings, were searched for eligible studies. Fixed and random-effects meta-analyses compared progression and survival by residual disease level across studies. Heterogeneity between comparisons was explored via type of surgery, disease stage, and type of adjuvant chemotherapy.
RESULTS: Of 2832 database and 16 supplementary search articles screened, 50 studies were selected; most were observational studies. The meta-analysis showed that median progression-free survival and overall survival decreased progressively with increasing residual disease (residual disease categories of 0 cm, > 0-1 cm and > 1 cm). Compared with no residual disease, hazard ratios (HR) for disease progression increased with increasing residual disease category (1.75 [95% confidence interval: 1.42, 2.16] for residual disease > 0-1 cm and 2.14 [1.34, 3.39] for residual disease > 1 cm), and also for reduced survival (HR versus no residual disease, 1.75 [ 1.62, 1.90] for residual disease > 0-1 cm and 2.32 [1.97, 2.72] for residual disease > 1 cm). All comparisons were significant (p < 0.05). Subgroup analyses showed an association between residual disease and disease progression/reduced survival irrespective of type of surgery, disease stage, or type of adjuvant chemotherapy.
CONCLUSIONS: This meta-analysis provided an update on the impact of residual disease following primary or interval cytoreductive surgery, and demonstrated that residual disease was still highly predictive of progression-free survival and overall survival in adults with ovarian cancer despite changes in ovarian cancer therapy over the last decade. Higher numerical categories of residual disease were associated with reduced survival than lower categories.
Pathology grading of prostate biopsy follows the rule that the highest International Society of Urological Pathology grade group (GG) is the GG assigned. This rule was developed in the systematic biopsy (SBx) era and makes sense when samples are from very different areas of the prostate. This rule has been kept for multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (MRI-TBx), for which multiple samples-targeted and systematic-are taken from small areas. In particular, if the results for SBx and MRI-TBx are discordant, the patient is assigned the higher GG. However, the most appropriate grading when MRI-TBx and SBx grades are discordant has never been investigated empirically. A cohort of patients who have undergone SBx and MRI-TBx with long oncological follow-up does not yet exist. To estimate the risk of recurrence for every combination of biopsy and pathological grades, we used the GG on radical prostatectomy (RP) as a surrogate for GG on MRI-TBx GG surrogate. We analyzed data for 12 468 men who underwent SBx and RP at a tertiary referral center and assessed 5-yr biochemical recurrence-free survival (bRFS) for each pairwise combination of biopsy and surgical GG results. We found that for cases with discordant SBx and RP grades, the risk of recurrence was intermediate, irrespective of whether the highest grade was at RP or SBx. For instance, the 5-yr bRFS rate was 57% for men with GG 3 on RP and 60% for men with GG 3 on SBx, but 63% for men with RP GG 3 and SBx GG 2, and 79% for men with RP GG 2 and SBx GG 3. Translating these findings to MRI-TBx casts doubt on current grading practice: when GGs are discordant between SBx and MRI-TBx, the risk of biochemical recurrence risk is not driven by the highest grade but by an intermediate between the two grades. Our findings should motivate studies assessing long-term outcomes for patients undergoing both MRI-TBx and SBx with a view to empirically evaluating current grading practices. PATIENT SUMMARY: Patients with prostate cancer may undergo two biopsy types: (1) systematic biopsy, for which sampling follows a systematic template; and (2) targeted biopsy, for which samples are taken from lesions detected on scans. There may be a difference in prostate cancer grade identified by the two approaches. In such cases, the risk of cancer recurrence seems to be predicted by an intermediate grade between the lower and higher grades.
According to VA estimates, nearly 500,000 Veterans suffer from dementia. There is currently no cure for dementia. Ultimately, dementia will have a large impact on quality of life in Veterans and families, lead to expensive nursing home placement, and decrease life expectancy for patients and family caregivers. The experience of high burden in a caregiver for a Veteran with dementia increases the likelihood of permanent nursing home placement and can separate Veterans from their families. To address the high burden of caring for a Veteran with dementia, the investigators aim to study the effect of a rehabilitative intervention for family caregivers of Veterans with dementia. This novel approach will use video technology that can reach caregivers in rural areas who do not have easy access to major VA medical centers.